Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

SS Ramalingam, JE Gray, Y Ohe, BC Cho, J Vansteenkiste, C Zhou, T Reungwetwattana, Y Cheng, B Chewaskulyong, R Shah, KH Lee, P Cheema, M Tiseo, T John, MC Lin, F Imamura, R Hodge, Y Rukazenkov, J-C Soria, D Planchard